Univariate and multivariable analyses of clinicopathologic features associated with the number of WHO and mIWG organ damage findings
| Organ damage . | Variable . | Univariate . | Multivariable . | ||
|---|---|---|---|---|---|
| Estimate . | P value . | Estimate . | P value . | ||
| No. of WHO hematologic organ damage findings | Presence of any S/A/R mutations | 0.57 | .0014 | 0.34 | .27 |
| Number of mutated S/A/R genes | 0.29 | .0013 | 0.10 | .53 | |
| Presence of tier 1 S/A/R mutations | 0.40 | .028 | 0.017 | .94 | |
| Number of additional comutated genes | 0.070 | .016 | 0.029 | .44 | |
| No. of WHO nonhematologic organ damage findings | Previous therapy | −0.35 | .046 | −0.091 | .72 |
| Previous midostaurin | −0.37 | .041 | −0.22 | .39 | |
| Presence of any S/A/R mutations | 0.45 | .013 | 0.26 | .41 | |
| Number of mutated S/A/R genes | 0.22 | .017 | 0.077 | .64 | |
| Total number of WHO organ damage findings | Presence of any S/A/R mutations | 0.51 | <.0001 | 0.31 | .19 |
| Number of mutated S/A/R genes | 0.26 | <.0001 | 0.14 | .30 | |
| Presence of tier 1 S/A/R mutations | 0.35 | .0068 | 0.20 | .61 | |
| Number of tier 1 mutated S/A/R genes | 0.25 | .013 | −0.19 | .55 | |
| Number of additional comutated genes | 0.049 | .031 | 0.0012 | .97 | |
| No. of mIWG hematologic organ damage findings | BM mast cell burden (%) | 0.0086 | .023 | 0.012 | .003∗ |
| Presence of any S/A/R mutations | 0.49 | .016 | 0.22 | .53 | |
| Number of mutated S/A/R genes | 0.28 | .0077 | 0.27 | .17 | |
| No. of mIWG nonhematologic organ damage findings | Diagnosis of MCL† (reference: SM-AHN) | −0.50 | .042 | −0.70 | .012 |
| BM mast cell burden (%) | 0.006 | .039 | 0.013 | .00016∗ | |
| KIT D816V VAF (%) | 0.011 | .010 | 0.0093 | .071 | |
| Presence of any S/A/R mutations | 0.45 | .0041 | 0.098 | .76 | |
| Number of mutated S/A/R genes | 0.24 | .0032 | 0.20 | .30 | |
| Presence of tier 1 S/A/R mutations | 0.37 | .020 | 0.010 | .98 | |
| Number of tier 1 mutated S/A/R genes | 0.29 | .016 | 0.086 | .83 | |
| Total number of mIWG organ damage findings | Diagnosis of ASM‡ (reference: SM-AHN) | −0.41 | .046 | −0.19 | .34 |
| BM mast cell burden (%) | 0.007 | .0043 | 0.012 | <.001∗ | |
| Presence of any S/A/R mutations | 0.46 | .00033 | 0.074 | .75 | |
| Number of mutated S/A/R genes | 0.25 | .00015 | 0.27 | .052 | |
| Presence of tier 1 S/A/R mutations | 0.33 | .017 | 0.34 | .40 | |
| Number of tier 1 mutated S/A/R genes | 0.22 | .040 | −0.26 | .44 | |
| Organ damage . | Variable . | Univariate . | Multivariable . | ||
|---|---|---|---|---|---|
| Estimate . | P value . | Estimate . | P value . | ||
| No. of WHO hematologic organ damage findings | Presence of any S/A/R mutations | 0.57 | .0014 | 0.34 | .27 |
| Number of mutated S/A/R genes | 0.29 | .0013 | 0.10 | .53 | |
| Presence of tier 1 S/A/R mutations | 0.40 | .028 | 0.017 | .94 | |
| Number of additional comutated genes | 0.070 | .016 | 0.029 | .44 | |
| No. of WHO nonhematologic organ damage findings | Previous therapy | −0.35 | .046 | −0.091 | .72 |
| Previous midostaurin | −0.37 | .041 | −0.22 | .39 | |
| Presence of any S/A/R mutations | 0.45 | .013 | 0.26 | .41 | |
| Number of mutated S/A/R genes | 0.22 | .017 | 0.077 | .64 | |
| Total number of WHO organ damage findings | Presence of any S/A/R mutations | 0.51 | <.0001 | 0.31 | .19 |
| Number of mutated S/A/R genes | 0.26 | <.0001 | 0.14 | .30 | |
| Presence of tier 1 S/A/R mutations | 0.35 | .0068 | 0.20 | .61 | |
| Number of tier 1 mutated S/A/R genes | 0.25 | .013 | −0.19 | .55 | |
| Number of additional comutated genes | 0.049 | .031 | 0.0012 | .97 | |
| No. of mIWG hematologic organ damage findings | BM mast cell burden (%) | 0.0086 | .023 | 0.012 | .003∗ |
| Presence of any S/A/R mutations | 0.49 | .016 | 0.22 | .53 | |
| Number of mutated S/A/R genes | 0.28 | .0077 | 0.27 | .17 | |
| No. of mIWG nonhematologic organ damage findings | Diagnosis of MCL† (reference: SM-AHN) | −0.50 | .042 | −0.70 | .012 |
| BM mast cell burden (%) | 0.006 | .039 | 0.013 | .00016∗ | |
| KIT D816V VAF (%) | 0.011 | .010 | 0.0093 | .071 | |
| Presence of any S/A/R mutations | 0.45 | .0041 | 0.098 | .76 | |
| Number of mutated S/A/R genes | 0.24 | .0032 | 0.20 | .30 | |
| Presence of tier 1 S/A/R mutations | 0.37 | .020 | 0.010 | .98 | |
| Number of tier 1 mutated S/A/R genes | 0.29 | .016 | 0.086 | .83 | |
| Total number of mIWG organ damage findings | Diagnosis of ASM‡ (reference: SM-AHN) | −0.41 | .046 | −0.19 | .34 |
| BM mast cell burden (%) | 0.007 | .0043 | 0.012 | <.001∗ | |
| Presence of any S/A/R mutations | 0.46 | .00033 | 0.074 | .75 | |
| Number of mutated S/A/R genes | 0.25 | .00015 | 0.27 | .052 | |
| Presence of tier 1 S/A/R mutations | 0.33 | .017 | 0.34 | .40 | |
| Number of tier 1 mutated S/A/R genes | 0.22 | .040 | −0.26 | .44 | |
Including univariate associations significant at the P < .05 level. Negative estimates refer to an inverse relationship between variables. All predictor variables evaluated were AdvSM subtype, age at diagnosis, previous therapy, number of previous therapies, previous midostaurin, months between diagnosis and clinical trial screening, serum tryptase level, BM mast cell burden, KIT D816V VAF, presence of any S/A/R mutations, number of mutated S/A/R genes, presence of tier 1 S/A/R mutations, number of tier 1 mutated S/A/R genes, presence of any additional comutations beyond KIT D816V, number of additional comutations, presence of tier 1 additional comutations beyond KIT D816V, and number of additional tier 1 comutations. There were no significant associations at the univariate level for the following outcome variables: any WHO nonhematologic organ damage, any mIWG nonhematologic organ damage, and any mIWG organ damage.
Statistically significant at P < .05.
Diagnosis of ASM was also included in multivariable model fitting.
Diagnosis of MCL was also included in multivariable model fitting.